Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 Dec;30(6):958–960. doi: 10.1128/aac.30.6.958

Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis.

J Ariza, J Bosch, F Gudiol, J Liñares, P F Viladrich, R Martín
PMCID: PMC180631  PMID: 3813520

Abstract

The in vitro susceptibility of Brucella melitensis was examined vis-a-vis the clinical outcome in 75 patients with brucellosis. The initial MICs for Brucella isolates from patients who relapsed and from those who did not were similar. Furthermore, the MICs for isolates from patients whose infections relapsed were no different from those for original isolates. Our results clearly showed that neither initial nor subsequent antibiotic susceptibility plays a role in the likelihood of relapse of patients with brucellosis.

Full text

PDF
958

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ariza J., Gudiol F., Pallarés R., Rufí G., Fernández-Viladrich P. Comparative trial of co-trimoxazole versus tetracycline-streptomycin in treating human brucellosis. J Infect Dis. 1985 Dec;152(6):1358–1359. doi: 10.1093/infdis/152.6.1358. [DOI] [PubMed] [Google Scholar]
  2. Ariza J., Gudiol F., Pallarés R., Rufí G., Fernández-Viladrich P. Comparative trial of rifampin-doxycycline versus tetracycline-streptomycin in the therapy of human brucellosis. Antimicrob Agents Chemother. 1985 Oct;28(4):548–551. doi: 10.1128/aac.28.4.548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bertrand A., Roux J., Janbon F., Jourdan J., Jonquet O. Traitement de la brucellose par la rifampicine. Résultats préliminaires. Nouv Presse Med. 1979 Nov 12;8(44):3635–3639. [PubMed] [Google Scholar]
  4. Bosch J., Liñares J., López de Goicoechea M. J., Ariza J., Cisnal M. C., Martin R. In-vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitensis. J Antimicrob Chemother. 1986 Apr;17(4):459–461. doi: 10.1093/jac/17.4.459. [DOI] [PubMed] [Google Scholar]
  5. Buchanan T. M., Faber L. C., Feldman R. A. Brucellosis in the United States, 1960-1972. An abattoir-associated disease. Part I. Clinical features and therapy. Medicine (Baltimore) 1974 Nov;53(6):403–413. doi: 10.1097/00005792-197411000-00001. [DOI] [PubMed] [Google Scholar]
  6. Corbel M. J. Determination of the in vitro sensitivity of Brucella strains to rifampicin. Br Vet J. 1976 May-Jun;132(3):266–275. doi: 10.1016/s0007-1935(17)34686-9. [DOI] [PubMed] [Google Scholar]
  7. De Rycke J. Effect of rifampicin and tetracycline alone and in combination against Brucella suis. Ann Microbiol (Paris) 1980 Nov-Dec;131B(3):277–287. [PubMed] [Google Scholar]
  8. FOZ A., GARRIGA S. Relation entre la fixation du complément et les anticorps in complets (test de Coombs) dans la brucellose humaine. Rev Immunol Ther Antimicrob. 1954;18(4):288–298. [PubMed] [Google Scholar]
  9. Fountain M. W., Weiss S. J., Fountain A. G., Shen A., Lenk R. P. Treatment of Brucella canis and Brucella abortus in vitro and in vivo by stable plurilamellar vesicle-encapsulated aminoglycosides. J Infect Dis. 1985 Sep;152(3):529–535. doi: 10.1093/infdis/152.3.529. [DOI] [PubMed] [Google Scholar]
  10. Gutiérrez Altés A., Díez Enciso M., Peña García P., Campos Bueno A. In vitro activity of N-formimidoyl thienamycin against 98 clinical isolates of Brucella melitensis compared with those of cefoxitin, rifampin, tetracycline, and co-trimoxazole. Antimicrob Agents Chemother. 1982 Mar;21(3):501–503. doi: 10.1128/aac.21.3.501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hall W. H., Manion R. E. In vitro susceptibility of Brucella to various antibiotics. Appl Microbiol. 1970 Oct;20(4):600–604. doi: 10.1128/am.20.4.600-604.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hatten B. A., Sulkin S. E. Intracellular Production of Brucella L Forms I. Recovery of L Forms from Tissue Culture Cells Infected with Brucella abortus. J Bacteriol. 1966 Jan;91(1):285–296. doi: 10.1128/jb.91.1.285-296.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hatten B. A., Sulkin S. E. Intracellular production of Brucella L forms . II. Induction and survival of Brucella abortus L forms in tissue culture. J Bacteriol. 1966 Jan;91(1):14–20. doi: 10.1128/jb.91.1.14-20.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. MAGOFFIN R. L., SPINK W. W. The protection of intracellular brucella against streptomycin alone and in combination with other antibiotics. J Lab Clin Med. 1951 Jun;37(6):924–930. [PubMed] [Google Scholar]
  15. Morgan W. J., MacKinnon D. J., Lawson J. R., Cullen G. A. The rose bengal plate agglutination test in the diagnosis of brucellosis. Vet Rec. 1969 Dec 6;85(23):636–641. doi: 10.1136/vr.85.23.636. [DOI] [PubMed] [Google Scholar]
  16. Palenque E., Otero J. R., Noriega A. R. In vitro susceptibility of Brucella melitensis to new cephalosporins crossing the blood-brain barrier. Antimicrob Agents Chemother. 1986 Jan;29(1):182–183. doi: 10.1128/aac.29.1.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Philippon A. M., Plommet M. G., Kazmierczak A., Marly J. L., Nevot P. A. Rifampin in the treatment of experimental brucellosis in mice and guinea pigs. J Infect Dis. 1977 Oct;136(4):481–488. [PubMed] [Google Scholar]
  18. RUIZ CASTANEDA M. Laboratory diagnosis of brucellosis in man. Bull World Health Organ. 1961;24:73–84. [PMC free article] [PubMed] [Google Scholar]
  19. Rizzo-Naudi J., Griscti-Soler N., Ganado W. Human brucellosis: an evaluation of antibiotics in the treatment of brucellosis. Postgrad Med J. 1967 Aug;43(502):520–526. doi: 10.1136/pgmj.43.502.520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Robertson L., Farrell I. D., Hinchliffe P. M. The sensitivity of Brucella abortus to chemotherapeutic agents. J Med Microbiol. 1973 Nov;6(4):549–557. doi: 10.1099/00222615-6-4-549. [DOI] [PubMed] [Google Scholar]
  21. Roux J., Ramuz M., Serre J. C. Action de la chlortétracycline sur les brucella intracellulaires. Ann Inst Pasteur (Paris) 1969 Jan;116(1):49–62. [PubMed] [Google Scholar]
  22. SHAFFER J. M., KUCERA C. J., SPINK W. W. The protection of intracellular brucella against therapeutic agents and the bactericidal action of serum. J Exp Med. 1953 Jan;97(1):77–90. doi: 10.1084/jem.97.1.77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. SPINK W. W., BRADLEY G. M. Persistent parasitism in experimental brucellosis: attempts to eliminate brucellae with long-term tetracycline therapy. J Lab Clin Med. 1960 Apr;55:535–547. [PubMed] [Google Scholar]
  24. SPINK W. W., HALL W. H., MAGOFFIN R. Follow-up study of therapy in forty-eight culturally proved cases of brucellosis; streptomycin and sulfadiazine, aureomycin, and chloramphenicol (chloromycetin). AMA Arch Intern Med. 1951 Oct;88(4):419–432. doi: 10.1001/archinte.1951.03810100003001. [DOI] [PubMed] [Google Scholar]
  25. SPINK W. W. HOST-PARASITE RELATIONSHIP IN BRUCELLOSIS. Lancet. 1964 Jul 25;2(7352):161–164. doi: 10.1016/s0140-6736(64)90228-4. [DOI] [PubMed] [Google Scholar]
  26. SPINK W. W. Some biologic and clinical problems related to intracellular parasitism in brucellosis. N Engl J Med. 1952 Oct 16;247(16):603–610. doi: 10.1056/NEJM195210162471605. [DOI] [PubMed] [Google Scholar]
  27. Sande M. A., Mandell G. L. Effect of rifampin on nasal carriage of Staphylococcus aureus. Antimicrob Agents Chemother. 1975 Mar;7(3):294–297. doi: 10.1128/aac.7.3.294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Yogev R., Melick C., Glogowski W. In vitro development of rifampin resistance in clinical isolates of Haemophilus influenzae type b. Antimicrob Agents Chemother. 1982 Mar;21(3):387–389. doi: 10.1128/aac.21.3.387. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES